ASHBURN,
Va., Aug. 7, 2024 /PRNewswire/ -- The American
College of Clinical Pharmacology® (ACCP)
published a recent Position Paper entitled
"Unregulated Psychotropic Products."
Unregulated psychotropics, not approved by the US Food & Drug
Administration (FDA) yet widely available and used to induce
euphoria and relaxation, pose significant public health risks like
addiction, overdose and death. Despite their illegal status,
they are available in various forms like pills, powders and
extracts at many over-the-counter establishments, gas stations and
online websites, leading to their misuse and addiction. Kratom,
tianeptine and phenibut are three commonly misused and unregulated
psychotropics discussed in this paper, explaining their origins,
forms of availability, marketing strategies involved, and
opioid-like and other effects based on their
pharmacological drug receptor interactions. These interactions lead
to serious harm, causing various mild to severe adverse events such
as seizures, tremors, impaired cognition, anxiety and deaths from
overdose and misuse. This position statement emphasizes the
significant health risks and the need for caution with products
being misrepresented as dietary ingredients or herbal supplements.
It also outlines the existing regulatory measures taken by the US
FDA and additional necessary steps to limit the availability of
these unregulated products in the market. Building
on health risks and regulatory aspects, ACCP urges
business establishments to stop selling these unsafe and
unregulated psychotropic products.
About ACCP
ACCP is a non-profit association
providing accredited Continuing Education, publications and
career-enhancing opportunities to clinical pharmacology healthcare
professionals.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accp-position-statement-unregulated-psychotropic-products-302215630.html
SOURCE American College of Clinical Pharmacology